Abstract Details

Title The Effects of Disease Modifying Therapy on Retinal Structures in Relapsing Remitting Multiple Sclerosis Patients

Topic Multiple Sclerosis

Presentation(s) P3 - Poster Session 3 (5:30 PM-6:30 PM)

Poster/Presentation
Number 15-093

Objective Utilizing Optical Coherence Tomography (OCT) to assess the retinal structure effects of disease modifying therapy (DMT) drugs for Relapsing Remitting Multiple Sclerosis (RRMS) patients compared to healthy controls.

Background

The safety and efficacy of Glatiramer Acetate 20mg (GA20) and 40mg (GA40), as well as Fingolimod (FTY) has been well established in RRMS patients. It is also well known that MS patients experience retinal thinning and volume loss over the course of the disease. OCT is a quick, non-invasive tool utilized to quantify these retinal structures. Our study aims to assess the effects of these DMTs in RRMS patients in comparison with healthy controls.

Design/Methods

Ninety-five total participants were included in this cross-sectional analysis. Participants were divided into four groups: 29 RRMS patients on GA20 (mean age±SD; 48.3±7.4y, mean disease duration±SD; 10.4±6.5y), 23 RRMS patients on GA40 (mean age±SD; 43.7±8.5y, mean disease duration±SD; 6.8±5.0y), 27 RRMS patients on FTY (mean age±SD; 38.8±11.0y, mean disease duration±SD; 7.2±6.5y), and 16 healthy control participants (mean age±SD; 44.8±8.8y). All OCT scans were performed by a trained technician to quantify the thickness of the peripapillary retinal nerve fiber layer (pRNFL) and the volumes of the macula. A general linear model with multivariate analysis was used to analyze our data (SPSS vs 24). Age and disease duration were included as covariates for our analysis.

Results There was no significant difference in the effect observed between the different DMT treatment groups and healthy controls on the total macular volume (p=0.435). Similarly, there were no significant difference in the pRNFL thickness in the three DMT treatment groups and healthy controls (p=0.860).

Conclusions Our data suggests that these three DMT options for RRMS patients may have a neuroprotective role in the retina when compared to healthy control individuals. Further longitudinal studies should be conducted to confirm our findings.

Authors/Disclosures
Melody Gilroy, BS PRESENTER	Ms. Gilroy has nothing to disclose.
Samuel Lichtman-Mikol, BA (Wayne State University)	Mr. Lichtman-Mikol has nothing to disclose.
Rachel Darling	No disclosure on file
Carla E. Santiago-Martinez (Wayne State University)	Ms. Santiago-Martinez has nothing to disclose.
Evanthia Bernitsas, MD, FAAN (Wayne State School of Medicine)	Dr. Bernitsas has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Bernitsas has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Vanda. The institution of Dr. Bernitsas has received research support from Roche/Genentech.

��ɫ��

��ɫ��